EGFR and head and neck squamous cell carcinoma: Cetuximab (CTX), an EGFR‐targeting monoclonal antibody, was the first targeted therapy that received FDA approval in combination with RT to treat locally or regionally advanced HNSCC (Santuray et al,2018), showing reduced toxicity compared with standard RT+CDDP.